Previous close | 72.40 |
Open | 70.30 |
Bid | 68.30 |
Ask | 69.30 |
Strike | 200.00 |
Expiry date | 2025-01-17 |
Day's range | 70.30 - 70.30 |
Contract range | N/A |
Volume | |
Open interest | 17 |
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
Moderna is on the rise after the Food and Drug Administration delayed a decision on its RSV vaccine. But is MRNA stock, once again, a buy?
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.